T he episode of House that aired on Tuesday, March 6 included suspicions that the main character, Dr. Gregory House, might have a brain tumor that could not be successfully treated by conventional therapies. At about 9:33 pm (8:33 pm central and mountain time) the character of Dr. Robert Chase said, "They've got another trial going on at Duke. Fifteen percent extend their lives beyond five years. If you are positive for protein PHF…" Before he could finish the sentence, Dr. House cut him short. The brief remark was barely six seconds long. It didn't mention a specific therapy. But the character did say "Duke."
"The next morning people started calling up and saying, 'They mentioned your vaccine study on House,'' recalled John H. Sampson, MD, PhD, Associate Professor of Surgery and Assistant Professor of Pathology at Duke Comprehensive Cancer Center. "Actually they didn't specifically say it was a vaccine, but I guess that's what the majority of people took it to mean."
Dr. Sampson hadn't seen the show when it first aired, but, boy, did he hear about it. Colleagues and friends called and e-mailed their congratulations that his work was recognized on a hugely popular TV show. Patients and their families wanted to know if they could get the treatment.
"That often happens-even though it was mentioned in a fictional setting, people suddenly think, 'Well, maybe there's something out there that I don't know about, and it's important. So they do start calling up,"
One of the most interesting calls, he said, was a woman who had a cat with a brain tumor. "She absolutely insisted that we give her cat this vaccine," he said. "That was probably the oddest call we got."
The higher-ups at Duke were pleased with the surprise attention.
" 
'No Product Placement'
He said the mention of Duke was not any kind of "product placement," which he says they carefully avoid in any case. As the storyline involving brain cancer developed, he just wanted to toss in a casual reference to his friend's brain tumor experience. "That's why, when I was researching, I just threw into a Google search 'What's Duke doing now?' You know, give me something crazy that they are doing now. I found one and I mentioned it," he said.
But in addition to his friend, there were 24 million other viewers watching that episode-some of them with powerful personal reasons to read more than was intended into the mention of Duke's research.
"In general when patients call, they think we are sort of right around the corner from the breakthrough and the cure. And really that's not the way it's going to happen; it's going to be slow incremental advances," Dr. Sampson says.
Starting Phase III Trials
He said he is confident the therapeutic cancer vaccine they are working on will lead to new treatment options for some patients, but it's only now entering Phase III trials.
The approach attempts to stimulate an immune system assault on tumor cells with injections of a variant of epidermal growth factor receptor protein. at least one episode of DVT or PE compared with patients treated with oncedaily dalteparin (27 patients), with most of the difference occurring during the first month of treatment. The benefit was maintained over the six-month study period. Mortality rates were similar between the study groups at the end of the study.
S C R I P T D O C T O R : M E D I C I N E I N T H E M E D I A
"The CLOT study provides clinical evidence that Fragmin is more effective than traditional oral anticoagulant therapy in reducing risk of recurrent VTE in patients with cancer," Dr. Rickles said.
The drug had already been approved for prevention of DVT, which may lead to PE, in patients undergoing hip-replacement surgery, in at-risk patients undergoing abdominal surgery and in at-risk acutely ill patients whose mobility is severely restricted. Fragmin is also approved for prophylaxis of ischemic complications resulting from unstable angina and non-Q-wave myocardial infarction when used with aspirin.
O T T he FDA has approved a new indication for dalteparin (Fragmin) for the extended treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence of the problem in patients with cancer. The drug is the first low-molecular-weight heparin approved in the US for the extended treatment of recurrent VTE in patients with cancer. The condition of VTE includes deep vein thrombosis (DVT) and pulmonary embolism (PE).
"Cancer treatments and the disease itself put this patient population at significantly higher risk than non-cancer patients for developing DVT and PE," Frederick Rickles, MD, Clinical Professor of Medicine at George Washington University Medical Center, said in a news release. The approval was based on data from the CLOT study, which evaluated the safety and efficacy of dalteparin in reducing the recurrence of DVT/PE in patients with cancer, compared with an oral anticoagulant. The CLOT study showed that, during a sixmonth period, nearly twice as many patients (53) "It's really terrific. And let me tell you one of the good things about it: Sometimes, when you are on a show, you get interviewed or something like that, it can often be as negative for you personally as it is positive. Sometimes it causes jealousy, or maybe you get misquoted. But something like what happened with House is really in essence out of our control, we can't really be misquoted because we aren't really being quoted-it's just a fictional story."
The EGFRvIII vaccine has also been featured in Newsweek, and in March it was highlighted by Katie Couric on the CBS Evening News.
"That was sort of the biggest thing of late," Dr. Sampson said. "That story created quite a stir as well, but really about equal to the House story, if not less."
So a vague reference on House that didn't even mention the treatment by name got as much of a response as a series on the evening news that included interviews with him and others involved in the clinical trials? "Yeah, I would say so," Dr. Sampson said.
Even Kaplow, who started the whole thing with his "shout out" to a friend, was amazed by the impact at Duke.
"Who knew that anyone was listening to the show that carefully? I mean, honestly, the thing went by in like three seconds," he said.
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